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A b s t r a c t 
Background: Patients suffering from cardiogenic shock, with no response to conventional therapy, may significantly improve 
when put on support devices such as extracorporeal membrane oxygenation (ECMO), which maintains systemic and pulmonary 
circulation, and decongests the heart. This publication presents authors’ own experience in qualifying and treating patients 
with cardiogenic shock, with the use of veno-arterial (VA) ECMO modality.
Aim: The main goal of the study was to analyse factors influencing outcome of VA ECMO therapy in patients with cardiogenic 
shock. Survival data were compared for patients surviving treatment (n = 12, 41%), and for patients who died while VA ECMO.
Methods: Retrospective study included all patients treated between February 2009, when ECMO was first used in the clinic, 
and March 2015. Of those, 29 patients were treated with VA ECMO for respiratory support. Mean patient age was 42 years; 
19 (66%) patients were male, and 10 (34%) patients were female.
Results: Total in-hospital mortality rate was 59% (17/29). No difference was observed as to patient age, sex, body height, mode 
of hospital admission, comorbidities or left ventricular ejection fraction at hospital admission, when comparing survivors and 
patients who died despite treatment. The following parameters were analysed: number of days on VA ECMO, troponin levels 
during first days from treatment onset, platelet transfusions, and duration of mechanical ventilation. No significant differences 
were observed between the groups. Surviving patients were significantly longer hospitalised (p = 0.016), including a longer 
stay in the intensive care unit (p = 0.03).
Conclusions: VA ECMO is an acceptable therapy for patients in a severe state of cardiogenic shock. In-hospital mortality rate 
was 59%, and 41% patients (12 subjects) were successfully treated with VA ECMO in course of cardiogenic shock.
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INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) is a modality 
of external life support. The system enables long-lasting circu-
latory or respiratory support or can totally take over respiratory 
function in patients hospitalised in intensive care units (ICU). 
Approximately 2–6% patients develop cardiogenic shock after 
cardiosurgical procedures [1]. When haemodynamic instabil-
ity persists despite maximal doses of inotropic agents, direct 
mechanical support of circulation needs to be considered. 
This procedure requires though a completed surgical inter-
vention. Support systems such as ECMO decongest the heart 
while maintaining blood flow in both systemic and pulmonary 
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circulation. The decision to stop intensifying pharmacologic-
al stimulation, and to apply mechanical support should be 
made before organ hypoperfusion caused by long-lasting 
low ejection fraction (EF) syndrome causes development of 
irreversible injury.
First attempt to use external pump for supporting or 
replacing heart and lungs took place in 1953 when Gib-
bon constructed a “lung-heart machine”. For the first time, 
he successfully applied extracorporeal circulation, creating 
a cardiopulmonary bypass during the procedure of closing 
interatrial defect in a 18-year-old woman [2]. When appli-
cation of extracorporeal circulation became feasible in the 
operating room, attempts were initiated to facilitate the use 
of similar methods in ICU. Long-term application became 
reality after Hill et al. [3] successfully used extracorporeal 
circulation for 72 h in adults, and described these procedures 
in 1972. Since then, an enormous technological progress 
occurred, and more advanced ECMO devices were con-
structed. The attempts to develop ECMO therapy intensified 
in 2009, during the AH1N1 epidemics, when veno-venous 
circuit (VV ECMO) was used to prevent critical organ hypoxia, 
and thus facilitated pharmacological treatment of the most 
severe infections. Since 1989, Extracorporeal Life Support 
Organisation (ELSO) has recorded ECMO treatment proce-
dures in more than 33,000 neonates, 15,000 children and 
13,000 adults [4]. Thanks to the presence of oxygenator and 
centrifugal pump, ECMO device may provide extracorporeal 
circulatory support both in pulmonary and in systemic circuit. 
The most important indication for ECMO therapy in adults 
with cardiac insufficiency is cardiogenic shock [4]. Other pos-
sible applications include low EF syndrome with hypotension, 
organ hypoperfusion demonstrating with oliguria and acidosis 
despite adequate fluid therapy and vascular bed filling. The 
device should be implanted in case of cardiogenic shock 
persisting despite adequate administration of inotropic and 
vasoactive drugs. Septic shock is an indication for ECMO 
therapy in veno-atrial (VA) configuration in many institutions 
[4]. Successful application of extracorporeal warming for VA 
ECMO in cases of accidental hypothermia was described in 
some centres [5–8]. Recently, there is a tendency to use VA 
ECMO as a treatment of choice for hypotermic patients [9–13]. 
Extracorporeal life support may be an effective treatment in 
patients developing cardiogenic shock due to drug poisoning, 
not responding to conventional therapy [14].
Not all patients requiring vital function support are eli-
gible for ECMO therapy, which is contraindicated in cases of 
irreversible organ damage causing circulatory or respiratory 
insufficiency, massive haemorrhage, and in patients with 
contraindications to chronic heparinisation. In some centres, 
absolute contraindications to ECMO treatment include severe 
neurological damage, uncontrolled (disseminated) malig-
nancy, patient age of over 80 years or comorbidity impeding 
recovery [15].
METHODS
Study group
The study was performer in accordance with regulations 
of Declaration of Helsinki. As it was a register study, where 
patient-identifying data was not collected and therapeutic 
process was not to be affected, application for approval from 
the local bioethical committee was not required. Permission 
for manuscript preparation was granted from the hospital’s 
head manager. Study group included all consecutive patients 
treated at the Department of Anaesthesiology and Intensive 
Care, belonging to the Department of Cardiovascular Surgery 
and Transplantology, Jagiellonian University Medical College in 
Krakow. The included patients were treated with VA ECMO for 
cardiogenic shock. Excluded were 9 patients treated with VA 
ECMO due to accidental hypothermia. Study group comprised 
29 patients, and the observation period was from January 
2009 when ECMO was introduced in the department, to 
March 2015. Retrospective analysis included demographical 
data, mode of hospital admission, primary cause of initiating 
ECMO treatment, comorbidities, left ventricular EF (LVEF) 
at hospital admission, troponin profile under first 3 days of 
hospitalisation, duration of in-hospital stay, duration of stay 
in the ICU, duration of mechanical ventilation, deaths as well 
as complications of ECMO therapy.
In-hospital death was defined as decease of any cause 
occurring within 30 days from onset of ECMO therapy or after 
this period but during the same hospitalisation [16]. Renal 
insufficiency was diagnosed in patients having creatinine over 
177 µmol/L [17].
Therapy
Femoral vessel access was most often performed in right or 
left groin, with venous inflow to pump by a 22–24 F cannula 
and return via a 19–21 F cannula (currently used are cannu-
las from Bioline Coating Maquet, Germany). Life supporting 
device included a Rotaflow Console REF 706037 (Maquet, 
Germany), Heater Unit HU 35 (Maquet, Germany) and an 
oxygenator (Permanent Life Support Set “Bioline-Coating”, 
Maquet, Germany) with a set of cannulas. Femoral artery was 
accessed directly. Initial flow rate was set at 65 mL/kg/min, and 
then adjusted so as to obtain oxygenation of mixed venous 
blood SvO2 of 60–70%. FiO2 was set at 40–60% in order to 
obtain arterial blood saturation (paO2) between 150 mm Hg 
and 200 mm Hg and carbon dioxide partial pressure (paCO2) 
of 35–45 mm Hg. Activated coagulation time was kept at 
160–200 s, controlled by continuous heparin infusion. Mean 
arterial pressure was maintained at 60 mm Hg.
Many patients required vasopressor therapy directly 
after operation (epinephrine, norepinephrine, dobutamine). 
Echocardiography was performed in all patients for assess-
ment of LVEF. Haemoglobin concentration was maintained at 
8 mg/dL, with help of blood product infusions. Default plate-
let concentration was > 80,000/mL. Continuous infusion of 
www.kardiologiapolska.pl
ECMO in cardiogenic shock
1479
fentanyl and midazolam was performed for analgo-sedation 
during salvage controlled mechanical ventilation (respiratory 
volume 6 mL/kg ideal body mass, respiration frequency 
10/min, PEEP 4 cm H2O). Antibiotics were administered 
after consultations with the team responsible for managing 
in-hospital infections. 
Statistical analysis
Statistical analyses were performed using STATISTICA 10 PL 
software. Descriptive analyses were performed for selected 
variables, and presented on histograms. For quantitative 
variables, number and percentage were calculated for each 
subgroup, and presented on column graphs.
Logistic regression model was used for analysis of cor-
relations between qualitative and continuous variables with 
patient deaths. Odds ratio (OR) with 95% confidence interval 
(CI) was calculated for each significant correlation. If logistic 
regression could not be applied, c2 test was used.
Level of statistical significance was adopted for p value 
lower than 0.05. Student’s t test was used for comparison 
of two groups, and non-parametric Mann-Whitney test for 
comparison of variables of non-normal distribution [18].
RESULTS
Study group included 29 patients treated with VA ECMO, in-
cluding 19 (66%) males. Mean patient age was 42 years. Over-
all in-hospital mortality rate was 59% (17/29).
Factors influencing survival of patients treated with VA 
ECMO were then analysed. For this purpose, outcomes were 
compared between survivors (n = 12; 41%) and patients who 
died despite adequate extracorporeal membrane oxygenation 
therapy in VA configuration. Table 1 contains demographical 
data and general characteristics of subgroups, including co-
morbidities.
In 18 (62%) patients, ECMO therapy was administered 
due to inability to stop extracorporeal circulation or after 
cardiosurgical procedures. The remainder 11 (38%) patients 
required therapy due to a severe cardiogenic shock resulting 
from cardiac decompensation in course of cardiomyopathy 
or myocarditis.
Causes of ECMO therapy initiation after respective car-
diosurgical procedures are presented in Figure 1.
No differences were observed between survivors and 
deceased patients as to age, sex, body height, hospital admis-
sion mode, comorbidities or left LVEF at hospital admission. 
Logistic regression analysis did not identify any correlations 
neither between qualitative and continuous variables nor 
between deaths and demographical data (Table 2) or cause for 
ECMO therapy initiation (Table 3). No significant correlation 
was observed between deaths and comorbidities (Table 4).
Analysis of surviving patients as compared to deceased 
ones involved Student’s t-test or non-parametric Mann-Whit-
ney test, for variables of non-normal distribution (Table 5). 
The investigated variables included number of days on VA 
ECMO therapy, troponin levels during first days of therapy, 
transfusions of platelet concentrates, and duration of me-
chanical ventilation. No significant differences were observed 
between the groups. The surviving group had significantly 
longer hospitalisations in ICU (p = 0.03; Fig. 2) and duration 
of in-hospital stay (p = 0.016; Fig. 3).
Both groups of patients treated with VA ECMO ex-
perienced complications. Those included thrombostatic 
perturbations with necessity of transfusing blood products 
(n = 21, 72%), liver failure (n = 19, 66%), acute kidney 
injury necessitating continuous kidney replacement therapy 
(n = 10, 35%), and lower limb ischaemia (n = 10, 35%). 
Seven (27%) patients developed cardiac tamponade and un-
derwent re-thoracotomy. Four (14%) patients required pleural 
Table 1. Demographical data and patient characteristics in subgroups with respective comorbidities
Deceased Survived P
Sex (male/female) 12/5 7/5 0.4941
Age 42.0 ± 15.51 41.2 ± 13.78 0.7040
Body weight 76.6 ± 17.77 73.0 ± 9.64 0.0451
Body height 1.7 ± 0.08 1.7 ± 0.08 1.0000
BMI 27.9 ± 5.90 25.95 ± 5.05 0.6081
AH (yes/no) 7/10 2/10 0.1597
DM type 2 (yes/no) 3/14 1/11 0.4438
MI (yes/no) 7/10 2/10 0.1597
PCI (yes/no) 3/14 1/11 0.4438
Emergency admission to hospital (yes/no) 8/9 10/2 0.0641
EF at admission to hospital (median) 35.59 ± 20.53 (40) 27.08 ± 26.58 (10) 0.2449
AH — arterial hypertension; BMI — body mass index; DM — diabetes mellitus; EF — ejection fraction; MI — myocardial infarction;  
PCI — percutaneous coronary interventions
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Table 2. Logistic regression analysis of demographical characte- 
ristics influencing risk of patient death during VA ECMO therapy
OR CI P 
Sex 0.6 0.1–4.6 0.592
Age 1.0 0.1–1.1 0.877
Body weight 1.0 1.0–1.1 0.510
BMI 1.0 0.9–1.2 0.350 
BMI — body mass index; CI — confidence interval; OR — odds ratio
Table 3. Logistic regression analysis of risk factors for death 
during VA ECMO therapy (including indications for therapy)
OR CI P 
Post cardiac surgery 4.6 0.9–24,4 0.064
Ischaemic cardiomyopathy 0.8 0.2–4.4 0.822
Myocarditis 0.6 0.1–4.3 0.631
MVR 1.1 0.1–8.4 0.945
AVR 6.0 0.6–65.0 0.123
AAAsc 2.4 0.2–29.0 0.483
Pulmonary artery embolus 0.2 0.0–5.9 0.414
Circulatory decompensation 0.4 0.1–2.1 0.265
AAAsc — aneurysm of ascending aorta; AVR — aortic valve replacement; 
MVR — mitral valve replacement; CI — confidence interval; OR — odds ratio
Table 4. Logistic regression analysis of risk factors for death 
during VA ECMO therapy (comorbidities)
OR CI P 
Arterial hypertension 3.5 0.5–23 0.172
DM type 2 2.4 0.2–28 0.483
Previous MI 3.5 0.5–23 0.172
Status post PCI 2.4 0.2–29 0.483
Elective hospitalisation 0.2 0.03–1.2  0.058
Dyslipidaemia 2.7 0.4–18 0.279
IABP on admission 0.6 0.1–3.4 0.562
CI — confidence interval; DM — diabetes mellitus; IABP — intraaortic 
balloon pump; MI — myocardial infarction; OR — odds ratio
cavity drainage, and in 3 (10%) intracavitary electrodes were 
placed. There were no significant correlations between these 
complications and patient deaths (Table 6).
Positive blood cultures were obtained in 8 (28%) pa-
tients. Surviving patients were significantly longer hospitalised, 
and had longer periods in ICU, which increases markedly risk 
of infection.
Therapy using VA ECMO was effective in 12 (41%) of 
29 patients in severe cardiogenic shock. Decision to start 
ECMO treatment was in each case related to lack of clinical 
improvement and inefficacy of adequate standard therapeutic 
measures. Three (10%) patients after successful ECMO therapy 
were discharged home, 7 (24%) were transferred to cardiology 
departments for further therapy, and 2 (7%) were discharged 
to sanatoria for rehabilitation. 
DISCUSSION
Veno-arterial ECMO is an accepted therapeutic modality for 
patients in severe cardiogenic shock. In-hospital mortality 
rate was 59% in VA ECMO-treated patients in the presented 
study. Thus, 41% patients receiving this therapy successfully 
recovered from a severe cardiogenic shock. Those were, 
among others, patients after cardiosurgical interventions or 
patients who could not be put on extracorporeal circulation. 
Decision to initiate ECMO treatment following cardiac surgery 
was in most cases related to inability to stop extracorporeal 
circulation after the procedure, and inotrope medication 
was ineffective. Among these patients, 18 (62%) had ECMO 
implanted directly after surgical procedure, before transfer to 
ICU. Patients who developed cardiogenic shock not related to 
cardiac surgery were put on ECMO when vasopressor doses 
were as follows: epinephrine 8–10 µg/min, norepinephrine 
6–14 µg/min, dobutamine 5–10 µg/kg/min. In 9 (31%) pa-
tients ECMO was implanted less than 24 h from admission 
to ICU. In 2 subjects, therapy was initiated on respectively 
day 3 and day 7 from ICU admission, following unsuccessful 
attempts at haemodynamic stabilisation and application of 
intraaortic balloon pump. Both patients experienced a rapid 
Figure 1. Causes of ECMO therapy following respective cardiosurgical interventions; AAAsc — aneurysm of ascending aorta;  
AVR — aortic valve replacement; LV — left ventricle; MVR — mitral valve replacement
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decrease in EF by 5–10% and required increased doses of 
vasopressors, which triggered the decision to start extracor-
poreal support. 
In the presented study, authors describe own experience 
in VA ECMO therapy of patients in a severe state of cardio-
genic shock. The system can be applied using a central access 
but also by peripheral vascular access. In authors’ institution, 
peripheral access is preferred given the necessity of anticoagu-
lation treatment due to haemostatic disorders and because of 
infection risk. The study showed that surviving patients were 
much longer hospitalised, and treated in ICU, which explains 
high costs of therapy in this group. Technical characteristics 
and clinical profile of ECMO circulatory and respiratory 
support contribute to multitude of treatment indications. In 
the presented study, a modern mobile system was applied, 
enabling relocation of device together with the patient and 
continuation of treatment for a longer period. The device 
demonstrates a good steerability and flexible respiratory and 
circulatory support. Therapy with ECMO was successfully ap-
plied for recovery, before heart transplantation or by default 
in patient in accidental hypothermia [19]. Promising results 
were also described in ECMO treated patients with cardiac 
failure after medicinal poisoning [14]. Aubron et al. [20] point 
out that bleeding and coagulopathy are the most common 
complications in ECMO-treated patients, apart from neuro-
logical, vascular and infectious complications. These are also 
major risks of death in this patient population. Second most 
common group of complications includes haematogenic infec-
tions [20]. In the presented study, 72% patients experienced 
bleeding and coagulopathy, being the two most common 
Table 5. Variables affecting survival of VA ECMO-treated patients during hospitalisation in ICU
Deceased Survived P
Number of days on ECMO 8.18 ± 7.75 (5) 11.83 ± 7.16 (11) 0.1171
IABP on admission 0.24 ± 0.44 (0) 0.33 ± 0.49 (0) 0.6788
Troponin level, day 1 14.00 ± 29.09 (1.69) 2.57 ± 3.23 (0.74) 0.3238
Troponin level, day 2 20.78 ± 33.71 (2.66) 2.80 ± 3.40 (1.59) 0.2803
Troponin level, day 3 12.70 ± 18.79 (2.425) 2.07 ± 2.35 (1.33) 0.1890
Transfusion of platelet concentrates 9.12 ± 11.17 (4) 7.67 ± 6.98 (4) 0.7770
Number of days on mechanical ventilation 10.94 ± 11.04 (5) 13.58 ± 12.70 (10) 0.498540
Number of days in ICU 14.24 ± 15.41 (5) 24.75 ± 12.49 (27.5) 0.0301
Number of days in hospital 20.59 ± 27.94 (9) 35.42 ± 16.53 (32) 0.0161 
Values are expressed as mean ± standard deviation as well as median (in parentheses); ICU — intensive care unit; IABP — intraaortic balloon pump
Figure 2. Duration of stay in intensive care unit (ICU) for patients deceased (A) and patients surviving (B) during ECMO therapy
A B
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complications. No significant correlation was however ob-
served between these complications and mortality.
Survival data presented herein is consistent with reports 
from literature. Data from the ELSO registry showed survival 
rate of 39% in patients having cardiogenic shock [4]. Similar 
results were reported by Aissaoui et al. [21], Sakamoto et al. 
[22], and authors of many other case series or smaller stud-
ies. In the presented study, 28% patients had positive blood 
cultures. Impact of infection on results of ECMO therapy is 
controversial. Some authors suggest that sepsis or nosocomial 
infection correlate with risk of patient death [23, 24] whereas 
other reported no such link [25, 26]. Patients surviving ECMO 
therapy are significantly longer hospitalised and spend more 
time in ICU. Duration of the latter in-hospital stay poses 
a particular infection risk.
Limitations of the study
Several limitations of the study need to be pointed out. The 
study had retrospective character, and was based on data 
retrieved from medical journals. Besides, patient group was 
small, therefore conclusions on statistically significant correla-
tions should be treated with caution.
CONCLUSIONS
Successful ECMO therapy is based on close cooperation 
between anaesthesiologists, intensive care specialists, cardiac 
surgeons, perfusionists, pharmacologists and an experienced 
nursing staff. Therapy with VA ECMO may be successfully 
applied in severe cardiogenic shock, when conventional 
treatment is ineffective. 
Conflict of interest: none declared
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S t r e s z c z e n i e
Wstęp: Pacjenci we wstrząsie kardiogennym, nieodpowiadający na konwencjonalną terapię, mogą uzyskać wiele korzyści 
z leczenia za pomocą systemów wspomagających, takich jak membranowe natlenianie pozaustrojowe ECMO (extracorporeal 
membrane oxygenation), które zapewniają utrzymanie przepływów w krążeniu systemowym i/lub płucnym, odbarczając serce. 
Autorzy przedstawili doświadczenia własne w kwalifikowaniu i prowadzeniu terapii chorych we wstrząsie kardiogennym, 
u których zastosowano ECMO w konfiguracji żylno-tętniczej (VA ECMO).
Cel: Głównym celem badania było przeprowadzenie analizy czynników wpływających na przeżycie osób leczonych VA 
ECMO. Porównano grupę pacjentów, którzy przeżyli terapię (n = 12; 41%), z grupą chorych, którzy zmarli mimo zastoso-
wania VA ECMO.
Metody: Analiza retrospektywna dotyczyła pacjentów leczonych w okresie od lutego 2009 r., kiedy pierwszy raz zastosowano 
terapię ECMO w klinice autorów, do marca 2015 r. Badana populacja objęła 29 chorych leczonych za pomocą VA ECMO. 
Średni wiek pacjentów wynosił 42 lata; 19 osób stanowili mężczyźni (66%). Do badania włączono wszystkich kolejnych 
chorych, leczonych w ośrodku autorów, znajdujących się we wstrząsie kardiogennym, u których zastosowano VA ECMO jako 
układ wspomagający pracę płuc.
Wyniki: Całkowita szpitalna śmiertelność wynosiła 59% (17/29). Nie wykazano różnic między grupą zmarłych a grupą osób, 
które przeżyły, w odniesieniu do wieku, płci, wzrostu, trybu przyjęcia, chorób towarzyszących czy wartości frakcji wyrzutowej 
lewej komory ocenianej przy przyjęciu do szpitala. Analizie poddano liczbę dni leczenia za pomocą VA ECMO, stężenie tro-
ponin w pierwszych dobach wdrożenia terapii, przetoczenia koncentratu krwinek płytkowych, czas wentylacji mechanicznej. 
Nie wykazano istotnych różnic w obu grupach. Znamiennie dłuższy okazał się zarówno czas pobytu chorych na oddziale 
intensywnej terapii (p = 0,03), jak i czas pobytu w szpitalu (p = 0,016) w grupie pacjentów, którzy przeżyli.
Wnioski: Terapia za pomocą VA ECMO jest akceptowalną formą leczenia pacjentów w ciężkim wstrząsie kardiogennym. 
Szpitalna śmiertelność osób poddanych VA ECMO w niniejszym badaniu wynosiła 59%. Oznacza to, że u 12 (41%) chorych, 
u których wystąpił ciężki wstrząs kardiogenny, z powodzeniem zastosowano membranowe natlenianie pozaustrojowe.
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